Skip to main content

Articles

Page 33 of 60

  1. In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardi...

    Authors: Oliver Schnell, Lars Rydén, Eberhard Standl and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2017 16:128

    The Correction to this article has been published in Cardiovascular Diabetology 2017 16:150

  2. We investigated whether glycated albumin (GA) and its variability are associated with cardiovascular autonomic neuropathy (CAN) and further compared their associations with glycated hemoglobin (HbA1c).

    Authors: Ji Eun Jun, Seung-Eun Lee, You-Bin Lee, Ji Yeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2017 16:127
  3. Diabetes mellitus has long been associated with cardiovascular events. Nevertheless, the higher burden of traditional cardiovascular risk factors reported in high-income countries is offset by a more widesprea...

    Authors: José M. de Miguel-Yanes, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Manuel Méndez-Bailón, Javier de Miguel-Díez and Ana Lopez-de-Andrés
    Citation: Cardiovascular Diabetology 2017 16:126
  4. Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown...

    Authors: Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura and Tatsuya Atsumi
    Citation: Cardiovascular Diabetology 2017 16:125
  5. Despite best evidence-based treatment including statins, residual cardiovascular risk poses a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in particular elevated trigl...

    Authors: Jean-Charles Fruchart
    Citation: Cardiovascular Diabetology 2017 16:124
  6. The low-density lipoprotein cholesterol/apolipoprotein B (LDL-C/apoB) ratio has conventionally been used as an index of the LDL-particle size. Smaller LDL-particle size is associated with triglyceride (TG) met...

    Authors: Shigemasa Tani, Tsukasa Yagi, Wataru Atsumi, Kenji Kawauchi, Rei Matsuo and Atsushi Hirayama
    Citation: Cardiovascular Diabetology 2017 16:123
  7. Previous animal studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RAs) suppress arterial restenosis, a major complication of angioplasty, presumably through their direct action on vascula...

    Authors: Hideki Kushima, Yusaku Mori, Masakazu Koshibu, Munenori Hiromura, Kyoko Kohashi, Michishige Terasaki, Tomoyasu Fukui and Tsutomu Hirano
    Citation: Cardiovascular Diabetology 2017 16:122
  8. Abnormalities of endothelial cell function are proposed to be a critical factor underlying adverse cardiovascular outcomes in the setting of hyperglycaemia. While high-density lipoproteins (HDL) have been demo...

    Authors: Xing Chen, My-Ngan Duong, Peter J. Psaltis, Christina A. Bursill and Stephen J. Nicholls
    Citation: Cardiovascular Diabetology 2017 16:121
  9. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans. Several risk factors promote AF, among which diabetes mellitus has emerged as one of the most important. The growing recognit...

    Authors: Basil S. Karam, Alejandro Chavez-Moreno, Wonjoon Koh, Joseph G. Akar and Fadi G. Akar
    Citation: Cardiovascular Diabetology 2017 16:120
  10. NTproBNP and BNP levels are reduced in obese subjects, but population-based data comparing the pattern of this relationship in the full spectrum of insulin-resistance mediated conditions, overweight/obesity, m...

    Authors: Stefano Baldassarre, Salvatore Fragapani, Antonio Panero, Debora Fedele, Silvia Pinach, Manuela Lucchiari, Anna Rita Vitale, Giulio Mengozzi, Gabriella Gruden and Graziella Bruno
    Citation: Cardiovascular Diabetology 2017 16:119
  11. Microparticles (MPs) are vesicular structures shed from endothelial or circulating blood cells, after activation or apoptosis, and can be considered markers of vascular damage. We aimed to determine the levels...

    Authors: Alessandra Giannella, Claudia Maria Radu, Lorenzo Franco, Elena Campello, Paolo Simioni, Angelo Avogaro, Saula Vigili de Kreutzenberg and Giulio Ceolotto
    Citation: Cardiovascular Diabetology 2017 16:118
  12. Following publication of the original article [1], the authors reported that figure 2 had not been replaced with the correct figure as indicated in the proofs.

    Authors: Anxin Wang, Yang Sun, Xiaoxue Liu, Zhaoping Su, Junjuan Li, Yanxia Luo, Shuohua Chen, Jianli Wang, Xia Li, Zhan Zhao, Huiping Zhu, Shouling Wu and Xiuhua Guo
    Citation: Cardiovascular Diabetology 2017 16:117

    The original article was published in Cardiovascular Diabetology 2017 16:104

  13. Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes (T1D). A pro-calcific drift of circulating monocytes has been linked to vascular calcification and is marked by the surface express...

    Authors: Ernesto Maddaloni, Yu Xia, Kyoungmin Park, Stephanie D’Eon, Liane J. Tinsley, Ronald St-Louis, Mogher Khamaisi, Qian Li, George L. King and Hillary A. Keenan
    Citation: Cardiovascular Diabetology 2017 16:116
  14. The role of advanced glycation end products (AGEs) and their soluble receptor (sRAGE) on the progression and prognosis of acute heart failure (HF) was analysed in relation with metabolic parameters as body com...

    Authors: Beatriz Paradela-Dobarro, Ángel Fernández-Trasancos, Diana Bou-Teen, Sonia Eiras, Rocío González-Ferreiro, Rosa M. Agra, Alfonso Varela-Román, Ana I. Castro-Pais, Marcos C. Carreira, Felipe F. Casanueva, Ezequiel Álvarez and José R. González-Juanatey
    Citation: Cardiovascular Diabetology 2017 16:115
  15. Good glycaemic control in type 2 diabetes (T2DM) protects the microcirculation. Current guidelines suggest glycaemic targets be relaxed in advanced diabetes. We explored whether disease duration or pre-existin...

    Authors: F. Casanova, D. D. Adingupu, F. Adams, K. M. Gooding, H. C. Looker, K. Aizawa, F. Dove, S. Elyas, J. J. F. Belch, P. E. Gates, R. C. Littleford, M. Gilchrist, H. M. Colhoun, A. C. Shore, F. Khan and W. D. Strain
    Citation: Cardiovascular Diabetology 2017 16:114
  16. In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagli...

    Authors: Pia S. Pollack, Kristina D. Chadwick, David M. Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal and David W. Boulton
    Citation: Cardiovascular Diabetology 2017 16:113
  17. Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin in the United States,...

    Authors: Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Edward A. O’Neill, Samuel S. Engel, Keith D. Kaufman and Eseng Lai
    Citation: Cardiovascular Diabetology 2017 16:112
  18. Type 2 diabetes mellitus (T2DM) might aggravate the carotid plaque vulnerability, and increase the risk for ischemic stroke. Few studies reported the acute stroke subtype with carotid plaque characteristics in...

    Authors: Beibei Sun, Xiao Li, Xiaosheng Liu, Xiaoqian Ge, Qing Lu, Xihai Zhao, Jun Pu, Jianrong Xu and Huilin Zhao
    Citation: Cardiovascular Diabetology 2017 16:111
  19. Purpose: to establish if exercise training improves clinical outcomes in people with metabolic syndrome (MetS). Registered with PROSPERO international prospective register of systemati...

    Authors: C. Ostman, N. A. Smart, D. Morcos, A. Duller, W. Ridley and D. Jewiss
    Citation: Cardiovascular Diabetology 2017 16:110
  20. Secreted frizzled-related protein (Sfrp)5 has beneficial effects on insulin sensitivity, inflammation and cardiovascular risk in different mouse models, but its relevance for cardiometabolic diseases in humans...

    Authors: Maren Carstensen-Kirberg, Julia M. Kannenberg, Cornelia Huth, Christa Meisinger, Wolfgang Koenig, Margit Heier, Annette Peters, Wolfgang Rathmann, Michael Roden, Christian Herder and Barbara Thorand
    Citation: Cardiovascular Diabetology 2017 16:109
  21. The triglyceride glucose (TyG) index has been considered a simple surrogate marker of insulin resistance. However, few studies have investigated the relationship between the TyG index and coronary artery calci...

    Authors: Min Kyung Kim, Chul Woo Ahn, Shinae Kang, Ji Sun Nam, Kyung Rae Kim and Jong Suk Park
    Citation: Cardiovascular Diabetology 2017 16:108
  22. Statins may increase the risk of new-onset diabetes and adversely affect glycaemic control, but their effects on the glycemic response and mortality outcomes following commencement of insulin therapy in patien...

    Authors: Uchenna Anyanwagu, Jil Mamza, Richard Donnelly and Iskandar Idris
    Citation: Cardiovascular Diabetology 2017 16:107
  23. The relationship between fibroblast growth factor 21 (FGF21) and cardiovascular disease has been well established in recent studies. This study aimed to investigate the relationship between FGF21 and left vent...

    Authors: Yun Shen, Xueli Zhang, Xiaoping Pan, Yiting Xu, Qin Xiong, Zhigang Lu, Xiaojing Ma, Yuqian Bao and Weiping Jia
    Citation: Cardiovascular Diabetology 2017 16:106
  24. Diabetes has been reported to be associated with an increased relative risk for mortality, with estimates ranging from 1.1 to 2.1. Findings are inconsistent regarding modification of the risk by gender and by ...

    Authors: Inbar Zucker, Tamy Shohat, Rachel Dankner and Gabriel Chodick
    Citation: Cardiovascular Diabetology 2017 16:105
  25. The relationship between changes in proteinuria and myocardial infarction (MI) remains unclear in people with diabetes or pre-diabetes. We aimed to evaluate the predictive value and independent role of changes...

    Authors: Anxin Wang, Yang Sun, Xiaoxue Liu, Zhaoping Su, Junjuan Li, Yanxia Luo, Shuohua Chen, Jianli Wang, Xia Li, Zhan Zhao, Huiping Zhu, Shouling Wu and Xiuhua Guo
    Citation: Cardiovascular Diabetology 2017 16:104

    The Erratum to this article has been published in Cardiovascular Diabetology 2017 16:117

  26. We aimed to investigate the efficacy of ascorbic acid and acetylsalicylic acid among type II diabetes mellitus patients using metformin (only) for diabetes management therapy.

    Authors: Syed Wasif Gillani, Syed Azhar Syed Sulaiman, Mohi Iqbal Mohammad Abdul and Mirza R. Baig
    Citation: Cardiovascular Diabetology 2017 16:103
  27. High admission blood glucose (ABG) level has been associated with a poor short-term outcome among non-diabetic patients with heart failure (HF). We aimed to investigate the association between ABG levels and l...

    Authors: Osnat Itzhaki Ben Zadok, Ran Kornowski, Ilan Goldenberg, Robert Klempfner, Yoel Toledano, Yitschak Biton, Enrique Z. Fisman, Alexander Tenenbaum, Gregory Golovchiner, Ehud Kadmon, Alexander Omelchenko, Tuvia Ben Gal and Alon Barsheshet
    Citation: Cardiovascular Diabetology 2017 16:102
  28. Secondary prevention of cardiovascular disease (CVD) has improved immensely during the past decade but controversies persist on cardiovascular benefits among women with diabetes. We investigated 11-year trends...

    Authors: Anthony A. Laverty, Alex Bottle, Sung-Hee Kim, Bhakti Visani, Azeem Majeed, Christopher Millett and Eszter P. Vamos
    Citation: Cardiovascular Diabetology 2017 16:100
  29. High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascu...

    Authors: Silvia Giovannini, Giovanni Tinelli, Federico Biscetti, Giuseppe Straface, Flavia Angelini, Dario Pitocco, Luciana Mucci, Raffaele Landolfi and Andrea Flex
    Citation: Cardiovascular Diabetology 2017 16:99
  30. Neutrophil gelatinase-associated lipocalin (NGAL), an acute phase protein released by neutrophils, has been described as biomarker of inflammatory states. Type 2 diabetes mellitus (T2DM) is characterized by in...

    Authors: W. Eilenberg, S. Stojkovic, A. Piechota-Polanczyk, A. Kaider, N. Kozakowski, W. J. Weninger, J. Nanobachvili, J. Wojta, I. Huk, S. Demyanets and C. Neumayer
    Citation: Cardiovascular Diabetology 2017 16:98
  31. Acute myocardial infarction (AMI) patients with type 2 diabetes mellitus are known to present with multiple vessel lesions during coronary angiography. The underlying mechanism remains elusive and there is a s...

    Authors: Jianqing She, Yangyang Deng, Yue Wu, Yulong Xia, Hongbing Li, Xiao Liang, Rui Shi and Zuyi Yuan
    Citation: Cardiovascular Diabetology 2017 16:97
  32. Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14++CD16+ ...

    Authors: Naofumi Yoshida, Hiroyuki Yamamoto, Toshiro Shinke, Hiromasa Otake, Masaru Kuroda, Daisuke Terashita, Hachidai Takahashi, Kazuhiko Sakaguchi, Yushi Hirota, Takuo Emoto, Hilman Zulkifli Amin, Taiji Mizoguchi, Tomohiro Hayashi, Naoto Sasaki, Tomoya Yamashita, Wataru Ogawa…
    Citation: Cardiovascular Diabetology 2017 16:96
  33. Newer oral antidiabetic drug classes are expanding treatment options for type 2 diabetes mellitus (T2DM); however, concerns remain. The objective was to assess relative risk of heart failure hospitalization of...

    Authors: Santosh Gautam, Abiy Agiro, John Barron, Thomas Power, Harry Weisman and Jeff White
    Citation: Cardiovascular Diabetology 2017 16:93
  34. LADA is probably the most prevalent form of autoimmune diabetes. Nevertheless, there are few data about cardiovascular disease in this group of patients. The aim of this study was to investigate the frequency ...

    Authors: Marta Hernández, Carolina López, Jordi Real, Joan Valls, Emilio Ortega-Martinez de Victoria, Federico Vázquez, Esther Rubinat, Minerva Granado-Casas, Nuria Alonso, Teresa Molí, Angels Betriu, Albert Lecube, Elvira Fernández, Richard David Leslie and Dídac Mauricio
    Citation: Cardiovascular Diabetology 2017 16:94
  35. Microvascular disease is associated with a high risk of macrovascular events in patients with type 2 diabetes, but the impact of macrovascular disease on the risk of microvascular events remains unknown. We so...

    Authors: Kamel Mohammedi, Mark Woodward, Michel Marre, Stephen Colagiuri, Mark Cooper, Stephen Harrap, Giuseppe Mancia, Neil Poulter, Bryan Williams, Sophia Zoungas and John Chalmers
    Citation: Cardiovascular Diabetology 2017 16:95
  36. A previous genome-wide association study showed that a genetic variant of sortilin was associated with the risk of coronary artery disease (CAD). However, the role of circulating sortilin is still unknown. We ...

    Authors: Tae Jung Oh, Chang Ho Ahn, Bo-Rahm Kim, Kyoung Min Kim, Jae Hoon Moon, Soo Lim, Kyong Soo Park, Cheong Lim, HakChul Jang and Sung Hee Choi
    Citation: Cardiovascular Diabetology 2017 16:92
  37. Authors: Yu-Ming Chang, Chih-Chung Shiao, Ya-Ting Huang, I-Ling Chen, Chuan-Lan Yang, Show-Chin Leu, Hung-Li Su, Jsun-Liang Kao, Shih-Ching Tsai, Rong-Na Jhen and Ching-Cherng Uen
    Citation: Cardiovascular Diabetology 2017 16:90

    The original article was published in Cardiovascular Diabetology 2016 15:16

  38. Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular o...

    Authors: Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar and Wei-Chun Huang
    Citation: Cardiovascular Diabetology 2017 16:89
  39. To evaluate symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) as risk markers of cardiovascular disease, all-cause mortality and deterioration in renal function in a well characterised t...

    Authors: Emilie H. Zobel, Bernt Johan von Scholten, Henrik Reinhard, Frederik Persson, Tom Teerlink, Tine W. Hansen, Hans-Henrik Parving, Peter K. Jacobsen and Peter Rossing
    Citation: Cardiovascular Diabetology 2017 16:88
  40. Omentin-1, also known as Intelectin-1 (ITLN1), is an adipokine with plasma levels associated with diabetes, obesity, and coronary artery disease. Recent studies suggest that ITLN1 can mitigate myocardial ische...

    Authors: Louis A. Saddic, Sarah M. Nicoloro, Olga T. Gupta, Michael P. Czech, Joshua Gorham, Stanton K. Shernan, Christine E. Seidman, Jon G. Seidman, Sary F. Aranki, Simon C. Body, Timothy P. Fitzgibbons and Jochen D. Muehlschlegel
    Citation: Cardiovascular Diabetology 2017 16:87
  41. Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute ph...

    Authors: Michio Shimabukuro, Atsushi Tanaka, Masataka Sata, Kazuoki Dai, Yoshisato Shibata, Yohei Inoue, Hiroki Ikenaga, Shinji Kishimoto, Kozue Ogasawara, Akira Takashima, Toshiyuki Niki, Osamu Arasaki, Koichi Oshiro, Yutaka Mori, Masaharu Ishihara and Koichi Node
    Citation: Cardiovascular Diabetology 2017 16:86
  42. Patients with type 1 diabetes (T1D) are at increased risk of cardiovascular disease (CVD). Measures of high-density lipoprotein (HDL) function provide a better risk estimate for future CVD events than serum le...

    Authors: Martin Heier, Mark S. Borja, Cathrine Brunborg, Ingebjørg Seljeflot, Hanna Dis Margeirsdottir, Kristian F. Hanssen, Knut Dahl-Jørgensen and Michael N. Oda
    Citation: Cardiovascular Diabetology 2017 16:85
  43. Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors can potentially reduce the risk of cardiovascular mortality in patients with type 2 diabetes mellitus (T2DM). However, there is li...

    Authors: Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino and Takahisa Hirose
    Citation: Cardiovascular Diabetology 2017 16:84
  44. Although Japanese–Americans and native Japanese share the same genetic predispositions, they live different lifestyles, resulting in insulin resistance in Japanese–Americans. We investigated whether the quanti...

    Authors: Mitsunobu Kubota, Masayasu Yoneda, Norikazu Maeda, Haruya Ohno, Kenji Oki, Tohru Funahashi, Iichiro Shimomura and Noboru Hattori
    Citation: Cardiovascular Diabetology 2017 16:83
  45. To investigate the association between diabetic retinopathy (DR) and myocardial dysfunction in patients with type 2 diabetes and dilated cardiomyopathy (dCMP).

    Authors: Yoo-Ri Chung, Se-Jun Park, Ka Young Moon, Seoyoung Annie Choi, Hong-Seok Lim, Sung Wook Park, Jeong Hun Kim and Kihwang Lee
    Citation: Cardiovascular Diabetology 2017 16:82
  46. Red blood cell distribution width (RDW) is an established prognostic marker in acute and chronic heart failure (HF). Recent studies have pointed out a link among RDW, diabetes mellitus (DM) and inflammation. W...

    Authors: Andrew Xanthopoulos, Gregory Giamouzis, Andreas Melidonis, Takeshi Kitai, Efi Paraskevopoulou, Pinelopi Paraskevopoulou, Sotirios Patsilinakos, Filippos Triposkiadis and John Skoularigis
    Citation: Cardiovascular Diabetology 2017 16:81
  47. Emerging evidence suggests that specific (poly)phenols may constitute new preventative strategies to counteract cell oxidative stress and myocardial tissue inflammation, which have a key role in the patho-phys...

    Authors: Monia Savi, Leonardo Bocchi, Pedro Mena, Margherita Dall’Asta, Alan Crozier, Furio Brighenti, Donatella Stilli and Daniele Del Rio
    Citation: Cardiovascular Diabetology 2017 16:80
  48. Albuminuria is an established marker for endothelial dysfunction and cardiovascular risk in diabetes and prediabetes. Exercise induced albuminuria (EiA) appears earlier and may be a more sensitive biomarker fo...

    Authors: Rafael Y. Brzezinski, Inbal Etz-Hadar, Ayelet Grupper, Michal Ehrenwald, Itzhak Shapira, David Zeltser, Shlomo Berliner, Ori Rogowski, Roy Eldor and Shani Shenhar-Tsarfaty
    Citation: Cardiovascular Diabetology 2017 16:79

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions